Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

OSU-2S

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
DISCLOSURES Sharman: AbbVie: Consultancy, Honoraria, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; TG… Expand
Is this relevant?
2017
2017
The successful targeting of different malignancies by OSU-2S, encouraged us to design and synthesize a novel series of… Expand
Is this relevant?
2017
2017
OSU-2S is a FTY720 (Fingolimod) derivative that lacks immunosuppressive properties but exhibits strong anti-tumour activity in… Expand
  • figure 1
Is this relevant?
2016
2016
Background: Sorafenib (Nexavar®) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
In this issue of Blood, Zhang et al have uncovered that metformin, a first-line treatment for type 2 diabetes, can improve… Expand
Is this relevant?
2015
2015
Mantle-cell lymphoma (MCL) remains incurable despite numerous therapeutic advances. OSU-2S, a novel nonimmunosuppressive FTY720… Expand
  • figure 1
  • figure 2
Is this relevant?
2015
2015
Selective cytotoxicity to cancer cells without compromising their normal counterparts pose a huge challenge for traditional drug… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
OSU-2S is a novel anti-cancer and immune modulatory agent designed specifically to avert the immunosuppressive effects and… Expand
  • table 2
Is this relevant?
2011
2011
UNLABELLED Accumulating evidence suggests the therapeutic potential of the immunosuppressive agent FTY720 (fingolimod) in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
2011
2011
Abstract 2499 Despite development of numerous chemotherapeutic agents against Chronic Lymphocytic Leukemia (CLL), drug resistance… Expand
Is this relevant?